Shellie M. Callahan, Ph.D.
Affiliations: | 2005 | University of Texas at Austin, Austin, Texas, U.S.A. |
Area:
Molecular BiologyGoogle:
"Shellie Callahan"Parents
Sign in to add mentor| Maria A. Croyle | grad student | 2005 | UT Austin | |
| (Recombinant adenoviral-mediated alterations of cytochrome P450 3A2 and 2C11.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jonsson-Schmunk K, Wonganan P, Choi JH, et al. (2016) Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Wonganan P, Jonsson-Schmunk K, Callahan SM, et al. (2014) Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1191-201 |
| Callahan SM, Wonganan P, Croyle MA. (2008) Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virology Journal. 5: 111 |
| Callahan SM, Wonganan P, Obenauer-Kutner LJ, et al. (2008) Controlled inactivation of recombinant viruses with vitamin B2. Journal of Virological Methods. 148: 132-45 |
| Le HT, Boquet MP, Clark EA, et al. (2006) Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Human Gene Therapy. 17: 1095-111 |
| Callahan SM, Boquet MP, Ming X, et al. (2006) Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. The Journal of Gene Medicine. 8: 566-76 |
| Callahan SM, Ming X, Lu SK, et al. (2005) Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. The Journal of Pharmacology and Experimental Therapeutics. 312: 492-501 |
| Callahan SM, Wonganan P, Obenauer-Kutner LJ, et al. (2005) 414. Vitamin B2: A Key Component for Controlled Inactivation of Viruses Suitable for Biological Use Molecular Therapy. 11 |
| Boquet MP, Le HT, Clark EA, et al. (2005) 412. Renal Pathophysiology after Systemic Administration of a Recombinant Adenovirus: Changes in Drug Metabolism Based upon Vector Dose Molecular Therapy. 11 |
| Le HT, Boquet MP, Clark EA, et al. (2005) 148. The Transgene Cassette Is Not Fully Responsible for Alterations of Renal Cytochrome P450 Expression after Systemic Administration of Recombinant Adenovirus Molecular Therapy. 11 |